Press "Enter" to skip to content

AstraZeneca gets DGCI nod for marketing Dapagliflozin tablet in India

Biopharmaceutical major AstraZeneca on Saturday said it has received import and market permission from the Drugs Controller General of India (DGCI) in Form CT20 for Dapagliflozin film coated tablet 10mg. 

In a regulatory filing, AstraZeneca Pharma India said Dapagliflozin film coated tablet is an additional indication in adults for the treatment of heart failure with reduced ejection fraction.

“The receipt of this Import and Market permission paves way for launch of Dapagliflozin film coated tablet 10mg in India, subject to the receipt of related statutory approvals and licenses,” the Indian arm of the British-Swedish multinational pharmaceutical company said. 

Be First to Comment

Leave a Reply

Your email address will not be published.